Wanbury is locked at upper circuit at Rs. 44.20, up by 2.10 points or 4.99% from its previous closing of Rs. 42.10 on the BSE.
The scrip opened at Rs. 44.20 and has touched a high and low of Rs. 44.20 and Rs. 44.20 respectively. So far 12,000 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 93.20 on 31-Dec-2015 and a 52 week low of Rs. 37.30 on 01-Mar-2016.
Last one week high and low of the scrip stood at Rs. 44.50 and Rs. 39.65 respectively. The current market cap of the company is Rs. 88.26 crore.
The promoters holding in the company stood at 48.97%, while Institutions and Non-Institutions held 2.92% and 48.11% respectively.
Wanbury has successful completed US Food and Drug Administration (USFDA) inspection at its major API facility in Tanuku with one observation. The same was addressed and resolved by the Regulatory Team in time. The audit was carried out for a period of 5 days and concluded successfully.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation. The company’s major thrust area lies in Active Pharmaceutical Ingredient (API) sale in over 70 countries and Pan-India Formulation presence.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1486.35 |
Dr. Reddys Lab | 5962.50 |
Cipla | 1400.00 |
Zydus Lifesciences | 933.40 |
Lupin | 1580.00 |
View more.. |